If you’re taking raloxifene (Evista) because you have osteoporosis, a new study finds a probable added benefit: The drug may also significantly reduce your risk of developing breast cancer.The study, which appears in the Dec. 1 issue of the Journal of the National Cancer Institute, found that women taking raloxifene for eight years had a 59 percent lower risk of invasive breast cancer and a 66 percent lower risk of developing estrogen-receptor positive breast cancer, than women who had taken a placebo.
